www.laigobio.com A collaboration for the creation of a company specialized in the development of a new biological approach for the treatment of cancer and neurological disorders. Argobio and the Oncode Institute will support the company's development to Series A financing. Utrecht (Netherlands), and Paris (France), February 08th 2022 - ArgoBio and Oncode Institute have teamed up with Oncode Investigator Madelon Maurice, researcher and group leader at UMC Utrecht, to launch Laigo Bio, a new company in the emerging field of target protein degradation. The company has additionally secured funding from Oncode Bridge Fund and ArgoBio to further develop its proprietary pipeline of targeted immunotherapies SureTACsR. The SureTACsR technology platform is a novel approach in membrane protein degradation, applicable to a broad scope of disease applications. The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases. In contrast to other small molecule approaches, this results in an efficient and sustained degradation of target receptors, potentially resulting in superior efficacy in the clinic than modalities currently being employed by other emerging protein degradation technologies. Initially driven by Madelon Maurice, who will join as the Principal Investigator, Laigo Bio is gearing up for preclinical lead development in the coming months, generating proprietary biologics for a selection of targets to showcase its potential. Laigo Bio receives strong support from seasoned entrepreneurs Neill Moray Mackenzie at ArgoBio and Emil Pot at Oncode, who will prepare the company for a Series A investment round as it aims to initiate its first clinical studies in 2025. Dr. Neill Moray Mackenzie at ArgoBio is a veteran of the IO field and Mr Emil Pot is an IP & business development expert at Oncode with 25 years of experience in life sciences. Chris De Jonghe, Valorization Director of Oncode Institute, said: “SureTACsR is building on the innovative ideas that Dr. Maurice has initially validated with the support of Oncode’s Technology Development Fund. With the foundation of Laigo Bio, another exciting step forward is made towards the translation of Dr. Maurice’s innovations into effective, and tailored therapies for cancer patients. We are thrilled to join forces with ArgoBio in this initial seed round and consider it as a token of great confidence in the potential of this platform technology.” Madelon Maurice of the UMC Utrecht, said:“We are extremely happy that ArgoBio is supporting my long-standing research here at the UMC Utrecht on how to interfere with signalling alterations that drive oncogenesis and bringing a team of experienced scientists and entrepreneurs to help with its translation to the clinic.” Dr. Neill Moray Mackenzie of ArgoBio, said: “This is exactly why we put ArgoBio together last year – to fund these early-stage opportunities. I am especially pleased that Madelon Maurice, a renowned KOL in the field, is leading this novel approach to protein degradation which has great potential to open up a completely new biology in the field of cancer therapy.” Shobhit Dhawan of Oncode Bridge Fund, said: “Targeted protein degradation is an exciting space and has gained validation in clinical studies with many players now entering the field. One key differentiator here is sustained degradation of cell membrane bound proteins with a biologic, which is a very novel approach, and we believe holds a lot of promise in oncology and many neurological indications. We look forward to supporting Madelon, Neill and Emil in their journey at Laigo Bio.”

Argobio successfully facilitated fundraising and syndication process, following its earlier role in creating and pre-seed funding Laigo Bio Financing co-led by Kurma Partners and Curie Capital Laigo Bio is the second of eight Argobio-founded companies to achieve a seed financing to date Paris, France - 04 December 2025. Argobio Studio, the launchplatform for Europe’s best medicinal science, announced today the launch of Laigo Bio, with €11.5 million seed financing from a strong European investor syndicate. The financing was co-ledby Kurma Partners and Curie Capital, and includes Cancer Research Horizons, Angelini Ventures, Eurazeo, the Oncology Bridge Fund at the Oncode Institute, and ROM Utrecht region, in addition to Argobio. Laigo Bio, headquartered in Utrecht, the Netherlands, is pioneering novel and highly differentiated therapies using its proprietary SureTAC™ precision membrane protein degradation platform. The proceeds from the seed financing will be used to advance its oncology and immunology drug candidate pipeline. “We are pleased to take additional seed funding for Laigo Bio which we have supported since its inception. Its differentiated targeted membrane protein degradation platform enables access to disease mechanisms previously viewed as undruggable, holding tremendous potential benefit for human health. This new funding allows us to pivot into immunology, an emerging therapeutic area for TPD,” said Neill Moray Mackenzie, Partner and Entrepreneur in Residence at Argobio, and Chairman of Laigo Bio. “I am thrilled to welcome our new investors. Argobio has been instrumental in the creation and pre-seed funding of Laigo Bio; thanks to their vision and collaborative support, we are now able to advance further our novel approach to developing protein degradation drug candidates,” said Matthew Baker, Chief Executive Officer of Laigo Bio. “Our SureTAC platform is able to stimulate selective degradation of membrane-bound targets, which we believe could lead to more transformative therapies for patients with autoimmune and inflammatory diseases.” “This is our second company launch this year, which highlights the expertise and ability of our team of operational venture builders to rapidly translate transformational science into globally competitive biotech ventures. We now have a portfolio of eight companies that we have founded from the most cutting-edge European science,” added Thierry Laugel, Chairman of the Management Board of Argobio and Managing Partner at Kurma Partners. Another Argobio company, Elkedonia, announced an €11.25 million seed financing in June 2025 to advance discovery of its first-in-class non-hallucinogenic neuroplasticity enhancing antidepressant candidates for treatment-resistant depression. Laigo Bio (www.laigobio.com), an early stage biotech company based in the Netherlands, is the first company to leverage E3 ligase internalization for the selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases. Its proprietary SureTAC™ platform creates bispecific antibodies that target the optimal pair of E3 ligase and disease-causing target to stimulate ubiquitination and lysosomal degradation of the target protein with a high degree of specificity. Degradation of the target protein achieves deeper inhibition of disease pathways, while sparing the desirable functions of the target cell. Argobio Studio (www.argobiostudio.com) is thelaunch platformfor Europe’s best science. We turn cutting-edge science into globally competitive European companies pioneering breakthrough therapeutics for patients around the world. As operational venture builders, we reduce execution risk by co-founding, investing, and embedding our experienced, collaborative team, accelerating development with industrial rigor and speed toward value-creating milestones.

Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, the Netherlands - 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering novel and highly differentiated therapies using its proprietary SureTACs™ precision membrane protein degradation platform, today announces the successful completion of the second close of its seed financing round, securing an additional €5.5m, bringing the total raised to €17m. This latest investment comes from new co-lead investor Biovance Capital and existing co-lead investor Kurma Partners. The proceeds of the seed financing will be used to accelerate the development of Laigo’s Surface Removal Targeting Chimeras (SureTACs) oncology programs towards the clinic, as well as advance its three candidate programs for selected autoimmune and immunology indications, and graft rejection. Laigo’s proprietary SureTACs platform generates bispecific antibodies that pair the optimal E3 ligase with a disease-causing target protein to stimulate its ubiquitination and lysosomal degradation with a high degree of specificity. Laigo’s platform allows the development of first-in-class, dual targeted therapies that eliminate disease-driving membrane targets. Dr. Matthew Baker, Chief Executive Officer of Laigo Bio, said: “The second close of our seed financing round further validates the potential of our SureTACs platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases. The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in auto-immunity and immunology. We welcome Dr. João Incio to the Board of Directors.” Dr. João Incio, General Partner at Biovance Capital, added: “Laigo Bio has shown that its SureTACs degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety. We at Biovance Capital see phenomenal potential in Laigo’s technology and support its commitment to exploring an ever-evolving universe of new targets, including those currently considered undruggable.” Laigo is backed by a strong syndicate of leading international investors: Kurma Partners, Biovance Capital, Curie Capital, Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region, and Cancer Research Horizons. Laigo completed the initial close of its seed financing round in December 2025. About Laigo Bio Laigo Bio (www.laigobio.com), an early-stage biotech company based in the Netherlands, is pioneering the use of E3 ligase induced internalisation and selective degradation of membrane-bound targets involved in autoimmune and inflammatory diseases. Its proprietary SureTACs™ platform generates bispecific antibodies that pair the optimal E3 ligase with a disease-causing target protein to stimulate its ubiquitination and lysosomal degradation with a high degree of specificity. Degradation of the target protein achieves deeper inhibition of disease pathways compared to conventional therapeutics, while sparing healthy tissue and minimising side-effects. About SureTACs™ Surface Removal Targeting Chimeras (SureTACs™), developed in conjunction with Prof Madelon Maurice’s laboratory at the UMC Utrecht and Oncode Institute, are proprietary therapeutic candidates for targeted degradation of membrane proteins, that have been validated as disease drivers but have eluded drug discovery, and were long considered "undruggable". SureTACs are bispecific antibody molecules that induce degradation by bringing the cell surface target protein into close proximity with a surface E3 ligase enzyme, resulting in highly selective and deep inhibition of disease pathways in affected tissues. About Biovance Capital Biovance Capital (www.biovancecapital.com) is Portugal’s leading life sciences venture capital firm. The company manages Biovance Capital Fund I, a venture capital fund with a total of €60 million backed by the European Investment Fund and the European Commission through the Portugal Tech and InvestEU programmes, the largest Portuguese pharmaceutical company BIAL, the national promotional bank Banco Português de Fomento, , private investors such as Caixa Capital, Ageas Pensões, Fundo de Pensões EDP, in addition to other private investors from the USA and Europe. The fund invests in early-stage drug development companies across Europe, with a special focus on Southern Europe. About Kurma Partners Kurma Partners (www.kurmapartners.com) - Founded in Paris in 2009, Kurma Partners has become a key player in financing innovation to build the healthcare industry of tomorrow. Kurma invests in companies from their inception and to finance their growth, across the spectrum of the healthcare sector through its various franchises. These have grown with successive funds in early-stage biotechnology (Biofunds I, II, III and IV), digital health and early-stage diagnostics (Kurma Diagnostics and Kurma Diagnostics 2) and, more recently, growth capital (Kurma Growth Opportunities Fund). Kurma's teams, with a total of 25 people and 10 partners, are based in two offices, in Paris and Munich. They are deeply involved in the European ecosystem and have built up a solid network of international connections with prestigious research institutes, hospitals, entrepreneurs, industry and fellow investors. Kurma Partners is part of the Eurazeo group.